Clinical supply milestone reached for triple-negative breast cancer treatment12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.
Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics targeting essential kinases, has announced the completion of clinical trial supply manufacture for PMD-026.
PhoenixMD's lead program, PMD-026, is the first RSK inhibitor built for the treatment of triple-negative breast cancer (TNBC). The clinical trial supply was undertaken by STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, and is being used to support IND-enabling toxicology studies and an upcoming Phase I/Ib study in women with breast cancer.
In March 2018, the companies entered into a major manufacturing agreement, and have since produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices. This represents a significant milestone, accelerating PhoenixMD's Phase I readiness.
To further the collaboration, WuXi STA expanded its US operations to include capsule production under GMP regulatory compliance. Dr Minzhang Chen, CEO of WuXi STA, commented: "The opportunity to enable PhoenixMD's first-in-man studies came at an opportune moment for STA's San Diego facility."
"Our partnership with WuXi STA has been critical for PhoenixMD to advance this stage of our development. Working with such a high quality, globally recognized manufacturing partner has allowed us to rapidly advance PMD-026 through IND-enabling GLP toxicology studies and has enabled us to be ready to initiate our Phase I/Ib study with high quality API in capsules," said Sandra E. Dunn, CEO of PhoenixMD. "The rapid achievement of this milestone brings us one step closer to initiating our study for women suffering from breast cancer. More specifically, metastatic triple-negative breast cancer, which is the most deadly type of breast cancer. RSK2 is a promising new drug target for the treatment of TNBC, and PMD-026 is the first drug to ever reach clinical use against this novel target."
"The secret sauce in our success – teamwork. We truly appreciate the collaborative approach and commitment that WuXi STA has brought to the PMD-026 project," notes Dr Dunn.
FDA Approves rfxcel for Verification Router Service (VRS) Pilot
15 Aug 2019
rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.Read more
rfxcel Awarded ISO 9001:2015 Certification
14 Aug 2019
rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.Read more
How real-world data can revolutionise drug development
9 Aug 2019
Utilising the current data environment and its data pools for the benefit of advancing research.Read more
Using mobile phones to fight Alzheimer’s disease
8 Aug 2019
Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.Read more
Automation-compatible prepared culture media plate technology
6 Aug 2019
Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.Read more
Researchers develop 3D printed ingestible pill
4 Aug 2019
Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.Read more
Needle free: Erase wrinkles without injection
15 Jul 2019
Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06Read more
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.Read more
Cyclolab Ltd strengthens its position in the market
1 Jul 2019
Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation